看看医学和病毒学专家和大厂是不是真心的时候到了。

凡是以原始spike为目标，以防止spike与ace2结合为目的的抗体都失败了。

抗体疗法已经不再提及了。

疫苗也是一样，从根儿上选错的标的。因此，开发出来的抗体针对的是最容易变异的部分。

这么打下去，人是要被打废的。欧洲对此不无担心。很多报道已经高度质疑反复施打低效有安全隐患的疫苗的防疫方式了。

最近报道，人们终于找到病毒RBD上，历经N代进化，而依然维持不变的区域。并已经做出抗体。

现在就看，这些专家，大厂，政府，有没有为人之心，还是只为了赚钱。如果是后者，很可能，新的发现会被压制，而不会开发出针对性疫苗。因为那样做，大厂会损失一部分利润。

看看下一步发展吧。

https://scitechdaily.com/powerful-new-antibody-neutralizes-all-known-covid-variants/

 

What caused the SP1-77 antibody to be so broadly neutralizing? Structural studies by a collaborating team led by Bing Chen, Ph.D. and Jun Zhang, Ph.D. at Boston Children’s Hospital and the Haynes group at Duke, showed that SP1-77 works differently from current antibodies (either therapeutic antibodies or those we make in response to current vaccines).

Many of the existing antibodies work by attaching to the receptor-binding domain (RBD) of the spike in certain regions, preventing SARS-CoV-2 from binding to our cells’ ACE2 receptors, which is the initial step in infection. The SP1-77 antibody binds to the RBD as well, but in a completely different manner that does not prevent the virus from binding to ACE2 receptors.

Using a novel live-cell imaging platform described in a preprint, collaborators Alex Kreutzberger, Ph.D. and Tomas Kirchhausen, Ph.D., of Boston Children’s Hospital showed that SP1-77 prevents the virus from fusing its outer membrane with the membrane of the target cell. This thwarts the final necessary step that throws the door open to infection.

These features may inform the design of new SARS-CoV-2 vaccines. “SP1-77 binds the spike protein at a site that so far has not been mutated in any SARS-CoV-2 variant, broadly neutralizing current variants by a novel mechanism,” says Kirchhausen.